Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：T-DM1治疗HER2过表达转移性非小细胞肺癌

2019-01-20 MedSci MedSci原创

非小细胞肺癌HER2T-DM1
关注

HER2靶向治疗并不是HER2阳性非小细胞肺癌（NSCLC）的标准治疗方案。CLIN CANCER RES近期发表了一篇文章，研究HER2靶向抗体-药物偶联物T-DM1在接受过治疗的晚期HER2过表达NSCLC患者中的疗效和安全性。

HER2靶向治疗并不是HER2阳性非小细胞肺癌（NSCLC）的标准治疗方案。CLIN CANCER RES近期发表了一篇文章，研究HER2靶向抗体-药物偶联物T-DM1在接受过治疗的晚期HER2过表达NSCLC患者中的疗效和安全性。

研究纳入的患者患有HER2过表达的NSCLC，接受过铂类的化疗且存在EGFR突变或ALK基因重排的情况下接受过靶向治疗。根据HER2 IHC（2 +，3 +）将患者分为不同队列。所有患者均接受每3周静脉注射T-DM1 3.6 mg / kg治疗，直至出现疾病进展或不可耐受的毒性。主要终点是RECIST v1.1确定的总体反应率（ORR）。共49名患者接受T-DM1治疗（29 IHC 2 +，20 IHC 3+）。在IHC 2+队列中未观察到治疗反应。在IHC 3+队列中观察到4例部分反应。IHC 2+和3+队列的临床获益率分别为7％和30％。出现治疗反应的患者反应持续时间为2.9，7.3，8.3和10.8个月。两个队列的中位无进展生存期和总生存期相似。4例出现治疗反应的患者中有3例具有HER2基因扩增。

文章最后认为，T-DM1在HER2过表达（IHC 3+）晚期NSCLC患者中具有活性。需要对HER2通路改变进行更多的研究以寻找NSCLC中T-DM1治疗的目标人群； HER2 IHC作为单一参数不是充分的预测生物标志物。


原始出处：

Solange Peters, Rolf Stahel, et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. CLIN CANCER RES. January 2019 doi: 10.1158/1078-0432.CCR-18-1590

本文系梅斯医学（MedSci）原创编译整理，转载需授权！



版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059779, encodeId=90ef2059e79ed, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Mar 18 15:51:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958190, encodeId=b5b419581900d, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat May 11 19:51:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359081, encodeId=a8ff359081e4, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jan 24 05:38:55 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386462, encodeId=564d13864620e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472001, encodeId=b56914e200107, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-03-18 lingaifan

    #非小细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2059779, encodeId=90ef2059e79ed, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Mar 18 15:51:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958190, encodeId=b5b419581900d, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat May 11 19:51:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359081, encodeId=a8ff359081e4, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jan 24 05:38:55 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386462, encodeId=564d13864620e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472001, encodeId=b56914e200107, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-05-11 lq1767

    #过表达#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2059779, encodeId=90ef2059e79ed, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Mar 18 15:51:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958190, encodeId=b5b419581900d, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat May 11 19:51:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359081, encodeId=a8ff359081e4, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jan 24 05:38:55 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386462, encodeId=564d13864620e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472001, encodeId=b56914e200107, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-01-24 1e145228m78(暂无匿称)

    学习了，谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2059779, encodeId=90ef2059e79ed, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Mar 18 15:51:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958190, encodeId=b5b419581900d, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat May 11 19:51:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359081, encodeId=a8ff359081e4, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jan 24 05:38:55 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386462, encodeId=564d13864620e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472001, encodeId=b56914e200107, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-01-22 1249842em09(暂无昵称)

    #转移性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2059779, encodeId=90ef2059e79ed, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Mar 18 15:51:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958190, encodeId=b5b419581900d, content=<a href='/topic/show?id=48a294126c0' target=_blank style='color:#2F92EE;'>#过表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94126, encryptionId=48a294126c0, topicName=过表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19ad38, createdName=lq1767, createdTime=Sat May 11 19:51:00 CST 2019, time=2019-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359081, encodeId=a8ff359081e4, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jan 24 05:38:55 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386462, encodeId=564d13864620e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472001, encodeId=b56914e200107, content=<a href='/topic/show?id=c4d79344044' target=_blank style='color:#2F92EE;'>#转移性非小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93440, encryptionId=c4d79344044, topicName=转移性非小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=14b77195705, createdName=anan, createdTime=Tue Jan 22 09:51:00 CST 2019, time=2019-01-22, status=1, ipAttribution=)]
    2019-01-22 anan

    #转移性非小细胞肺癌#

    0

相关资讯

JCO：EGFR突变腺癌转化为非小细胞肺癌和其他神经内分泌肿瘤

大约3％至10％的EGFR突变的非小细胞肺癌（NSCLC）会转化为小细胞肺癌（SCLC），但其临床过程尚不明确。JCO近期发表了一篇文章研究这一问题。

CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌

肺癌是癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）占所有肺癌的85％，超过60％表达野生型EGFR（wtEGFR）。然而，EGFR酪氨酸激酶抑制剂（TKIs）在大多数wtEGFR肿瘤患者中作用有限。MERTK酪氨酸激是NSCLC的潜在治疗靶点，MRX-2843是一种新型MERTK选择性抑制剂，具有良好的临床转化性。CLIN CANCER RES近期发表了一篇文章，研究MERTK和EGFR抑制

JCLA：小泛素样修饰物/sentrin特异性肽酶1是非小细胞肺癌预后不良的危险因素？

SUMO/sentrin特异性肽酶1 (SENP1)与癌细胞的耐辐射相关，且在非小细胞肺癌(non - small cell lung cancer, NSCLC)中上调。本研究旨在探讨SENP1与NSCLC肿瘤化疗耐药的相关性。 研究人员采用免疫组化和实时定量PCR (qRT - PCR)方法检测Sentrin特异性肽酶1的表达谱。采用qRT PCR检测SENP1 mRNA的相对表达水平。

CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制

Osimertinib最初被批准用于治疗T790M阳性非小细胞肺癌（NSCLC），最近用于EGFR -mutant NSCLC的一线治疗。但是osimertinib的耐药机制尚不完全清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。

NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

ARCH PATHOL LAB MED：使用当前和近期分类的非小细胞肺癌的病理学家间诊断协议

病理学家诊断协议（IPDA）的测量应该允许病理学家改进当前的诊断标准和疾病分类。本研究通过最近的NSCLC重新分类，确定如何通过向苏木精 - 伊红（H＆E）添加一组粘蛋白和免疫组织化学（IHC）染色来影响病理学家诊断非小细胞肺癌（NSCLC）的IPDA。 基于网络的调查，研究人员向22名执业病理学家提供54个NSCLC病例的核心图像进行诊断，最初仅作为H＆E，然后为H＆E加粘蛋白和4个IHC

Baidu
map
Baidu
map
Baidu
map